Cargando…

Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB

BACKGROUND: Delamanid (DLM) tablets are recommended for the treatment of rifampicin-resistant TB. However, no liquid or dispersible tablet formulation of DLM is currently commercially available for patients with challenges ingesting these tablets. The aim of this study was to develop stable extempor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Taneja, R., Nahata, M. C., Scarim, J., Pande, P. G., Scarim, A., Hoddinott, G., Fourie, C. L., Jew, R. K., Schaaf, H. S., Garcia-Prats, A. J., Hesseling, A. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Union Against Tuberculosis and Lung Disease 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879082/ https://www.ncbi.nlm.nih.gov/pubmed/36853133 http://dx.doi.org/10.5588/ijtld.22.0329

Ejemplares similares

Extemporaneously compounded liquid formulations of clofazimine
por: Taneja, R., et al.
Publicado: (2023)

A novel home-based method for preparing suspensions of anti-TB drugs
por: Taneja, R., et al.
Publicado: (2023)

Stable, compounded bedaquiline suspensions to support practical implementation of pediatric dosing in the field
por: Taneja, R., et al.
Publicado: (2023)

Pediatric delamanid treatment for children with rifampicin-resistant TB
por: Tyeku, N., et al.
Publicado: (2022)

Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial
por: Garcia-Prats, Anthony J., et al.
Publicado: (2022)

Injectable-free regimens containing bedaquiline, delamanid, or both for adolescents with rifampicin-resistant tuberculosis in Khayelitsha, South Africa
por: Mohr-Holland, Erika, et al.
Publicado: (2020)

Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa
por: Mohr, Erika, et al.
Publicado: (2018)

Six-Month Response to Delamanid Treatment in MDR TB Patients
por: Hewison, Cathy, et al.
Publicado: (2017)

Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use
por: Hafkin, Jeffrey, et al.
Publicado: (2017)

The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
por: Khan, Uzma, et al.
Publicado: (2019)

Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort( )
por: Hewison, Catherine, et al.
Publicado: (2022)

TB programme stakeholder views on lessons from the COVID-19 response in South Africa
por: Myburgh, H., et al.
Publicado: (2023)

Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Publicado: (2023)

Therapeutic Failure and Acquired Bedaquiline and Delamanid Resistance in Treatment of Drug-Resistant TB
por: Millard, James, et al.
Publicado: (2023)

Smart Sugar? The Sugar Conspiracy
por: Damle, S. G.
Publicado: (2017)

Early interactions with newly diagnosed TB patients in hospital can support linkage to care
por: Viljoen, L., et al.
Publicado: (2022)

Replacement of sugar in the product formulation of “Bomboyson” by jaggery
por: Gartaula, Ghanendra, et al.
Publicado: (2014)

Early mortality during rifampicin-resistant TB treatment
por: Mohr-Holland, E., et al.
Publicado: (2022)

Formulation of Sugar/Hydrogel Inks for Rapid Thermal Response 4D Architectures with Sugar-derived Macropores
por: Ko, Hyojin, et al.
Publicado: (2020)

Attractive Sugar Bait Formulation for Development of Attractive Toxic Sugar Bait for Control of Aedes aegypti (Linnaeus)
por: Kumar, Sarita, et al.
Publicado: (2022)

Formulation and Scale-up of Delamanid Nanoparticles via Emulsification for Oral Tuberculosis Treatment
por: Caggiano, Nicholas J., et al.
Publicado: (2023)

Sugar
por: White, John R.
Publicado: (2018)

Sustained absorption of delamanid from lipid-based formulations as a path to reduced frequency of administration
por: Ramirez, Gisela, et al.
Publicado: (2020)

QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies
por: Ali, Ali Mohamed, et al.
Publicado: (2023)

On Blood-Sugar and Sugar Tolerance
Publicado: (1926)

Formulation and Characterization of Rifampicin Microcapsules
por: Sarfaraz, MD., et al.
Publicado: (2010)

Studying T Cell Responses to Hepatotropic Viruses in the Liver Microenvironment
por: Lopez-Scarim, Jarrett, et al.
Publicado: (2023)

Glycogen and Sugar
por: M'Kendrick, John G.
Publicado: (1878)

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)

Interleukin-1 Stimulates β-Cell Necrosis and Release of the Immunological Adjuvant HMGB1
por: Steer, Sarah A, et al.
Publicado: (2006)

Squeezing in with sugar
por: Wells, William A.
Publicado: (2001)

Hepatic iNKT cells produce type 2 cytokines and restrain antiviral T cells during acute hepacivirus infection
por: Raus, Svjetlana, et al.
Publicado: (2022)

Sugar
Publicado: (2001)

Sugars
Publicado: (1910)

Sugar
Publicado: (1874)

TB preventive therapy preferences among children and adolescents
por: Strauss, M., et al.
Publicado: (2023)

Starches, Sugars and Obesity
por: Aller, Erik E. J. G., et al.
Publicado: (2011)

A Lecture on Blood Sugar and Sugar Tolerance
por: Bhatia, S. L.
Publicado: (1925)

Sugar Intake: Are All Children Made of Sugar?
por: Diani, Lucia, et al.
Publicado: (2021)

Determination of the Sugar Content in High-Sugar Beverages
por: Kim, Suun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_scuac98fvja8lg7vo3u420ajro